- Статьи
- Science and technology
- One from all: Russia's first univaccine to protect against "super mutant" coronavirus
One from all: Russia's first univaccine to protect against "super mutant" coronavirus
Gamalei Center specialists have registered a new multivaccine with the Ministry of Health to protect against existing strains of coronavirus, including the "super mutant" PJ.2.1. It contains antigens for three variants of SARS-CoV-2 at once. According to the developers, the drug will remain effective against new subspecies of the virus that may appear in the future. According to experts, doctors need new, more effective vaccines. However, the ability of the development to provide protection against a rapidly changing virus has yet to be confirmed in practice.
Universal COVID-19 vaccine
Gamalei Center specialists have completed the registration procedure for a new multivaccine against SARS-CoV-2, which includes antigens of three coronavirus variants at once — the original Wuhan strain, as well as Delta and Omicron. Thanks to this composition, the drug provides protection against all known variants of COVID-19, including the "super mutant" PJ.2.1. According to the creators, the development should retain its properties against new genetic lines of the pathogen that may appear in the future.
— We have developed two multicurrency vaccines for the prevention of COVID-19 based on virus-like particles for nasal and parenteral (injection. — Izvestia) applications. These drugs are against multiple genotypes. They are effective not only for all the variants that were present, but also for newly emerging ones, since they consist of several proteins. Not only the surface ones, but also the capsid ones (a protective container for the genetic material of the virus. — Izvestia). Both variable and conservative. Therefore, the strains are changing, but the effectiveness of the vaccine remains the same, and if it decreases, then a little," Tatyana Grebennikova, head of the Laboratory of Molecular Diagnostics at the N.F. Gamaleya Federal Medical Research Center, told Izvestia.
The drug is ready for use, the developers are looking for partners to launch mass production.
One of the most actively spreading coronavirus variants in the world is considered to be PJ.2.1, which is also called a super mutant. Genetically, it differs markedly from its predecessors and is highly contagious. According to WHO, its symptoms are similar to those of the common cold and flu, so testing is necessary for an accurate diagnosis. As Izvestia wrote, an experimental study by German scientists showed that PJ.2.1 penetrates into human internal organs better than other subtypes of coronavirus.
The strain is a "super mutant" in Russia
On November 12, the media, citing Rospotrebnadzor of the Voronezh Region, reported that a "super mutant" had been identified in the region.
— Every year in autumn, there is an increase in the incidence of respiratory infections, including COVID-19. Strain PJ.2.1 is not a separate, fundamentally new virus, but a variant of SARS—CoV-2 (the virus that causes COVID-19), which belongs to the Omicron evolutionary lineage, the ministry clarified to Izvestia.
They added that this strain, as before, prevails among the circulating variants of the coronavirus.
The new vaccine contains antigens of the original Wuhan strain, Delta and Omicron. However, the second one has many subspecies, including PJ.2.1, which are noticeably different from the original version. Therefore, the ability of the vaccine to protect against new strains is still questionable, said Andrey Pozdnyakov, an infectious disease specialist at INVITRO.
— Rather, the vaccine is designed to protect against severe strains if they appear as a result of new mutations. Time will tell how much the level of antibodies in patients will match the stated indicators. As well as whether these antibodies can provide protection against new variants of the virus," he said.
According to the doctor, the drug is now needed primarily for patients with severe pathologies.
The Sputnik V vaccine was developed under emergency conditions, so the creation of a more advanced drug is not only possible, but also necessary, says Maria Vedunova, director of the Institute of Biology and Biomedicine at the Lobachevsky National Research University.
— The peculiarity of seasonal infections, including coronavirus, is that it is difficult to create a vaccine that provides long-term protection: these viruses mutate quickly. For example, after suffering from the flu, immunity is formed, but every year new variants of the virus appear, for which updated vaccines are being developed. SARS-CoV-2 also has new strains, so the drug's ability to protect against them is questionable," she noted.
According to immunologist Mikhail Bolkov, vaccines based on virus-like particles have proven themselves well. Due to the presence of several antigens, they are able to elicit a broader immune response. In addition, such drugs are safer than adenovirus vaccines, including Sputnik V: the body can produce antibodies to the adenovirus itself, which reduces the effectiveness of vaccination. However, it will be possible to judge the effectiveness of the new development only based on the results of its practical application.
According to Rospotrebnadzor, 608,000 cases of acute respiratory viral infections, influenza and COVID-19 were registered in the 46th week of 2026 (November 9-15). More than 2.8 thousand people fell ill with the flu. According to the results of virological monitoring, among the circulating respiratory viruses, pathogens of non—influenza etiology predominate - 79.5%. These include rhinoviruses (32.1%) and parainfluenza viruses (16.2%). Influenza viruses account for 20.3% of the detected cases. Variants A(H1N1), A(H3N2), B and C were found among them.
Переведено сервисом «Яндекс Переводчик»